Literature DB >> 27857112

Nivolumab for recurrent squamous-cell carcinoma of the head and neck.

.   

Abstract

Increased overall survival with nivolumab albeit only 7.5 months vs 5.1 months, and a better quality of life.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27857112     DOI： 10.1038/sj.bdj.2016.860

Source DB:  PubMed          Journal:  Br Dent J        ISSN： 0007-0610            Impact factor:   1.626


  2 in total

Review 1.  Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Assuntina G Sacco; Ezra E Cohen
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

2.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245
  2 in total
  1 in total

1.  Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab.

Authors:  Shujie Liu; Shuai Yan; Jie Zhu; Ruiqing Lu; Chujie Kang; Kang Tang; Jinfeng Zeng; Mingmei Ding; Zixiang Guo; Xianxin Lai; Yinan Jiang; Siqing Wu; Lihua Zhou; Litao Sun; Zhong-Wei Zhou
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.